{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:22:10Z","timestamp":1769606530162,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T00:00:00Z","timestamp":1479945600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["12\/127\/10"],"award-info":[{"award-number":["12\/127\/10"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13063-016-1683-8","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T00:46:34Z","timestamp":1479948394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Clare","family":"Brittain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Childs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lelia","family":"Duley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Harding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trish","family":"Hepburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garry","family":"Meakin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan A.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D. C.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,24]]},"reference":[{"key":"1683_CR1","unstructured":"Public Health England. Sexually transmitted infections and chlamydia screening in England, 2014. Health Protection Report 2015. https:\/\/www.gov.uk\/government\/statistics\/sexually-transmitted-infections-stis-annual-data-tables"},{"key":"1683_CR2","unstructured":"Public Health England. Surveillance of antimicrobial resistance in Neisseria gonorrhoeae. Key findings from the \u2018Gonococcal Resistance to Antimicrobials Surveillance Programme\u2019 (GRASP) and related surveillance data. 2014. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/476582\/GRASP_2014_report_final_111115.pdf ."},{"key":"1683_CR3","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1093\/clinids\/20.Supplement_1.S47","volume":"20","author":"JS Moran","year":"1995","unstructured":"Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis. 1995;20:S47\u201365.","journal-title":"Clin Infect Dis."},{"issue":"22","key":"1683_CR4","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1056\/NEJMc1203138","volume":"366","author":"S Duncan","year":"2012","unstructured":"Duncan S, Duncan CJ. The emerging threat of untreatable gonococcal infection. N Engl J Med. 2012;366(22):2136.","journal-title":"N Engl J Med"},{"key":"1683_CR5","unstructured":"Group GRASP. GRASP 2010 Report: The Gonococcal Resistance to Antimicrobials Surveillance Programme. Public Health England. 2011. http:\/\/webarchive.nationalarchives.gov.uk\/20140714084352\/ ."},{"issue":"3","key":"1683_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1128\/AAC.05760-11","volume":"56","author":"M Unemo","year":"2012","unstructured":"Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56(3):1273\u201380.","journal-title":"Antimicrob Agents Chemother"},{"key":"1683_CR7","doi-asserted-by":"crossref","unstructured":"Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill. 2011;16(6).","DOI":"10.2807\/ese.16.06.19792-en"},{"key":"1683_CR8","doi-asserted-by":"crossref","unstructured":"Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill. 2011;16(14).","DOI":"10.2807\/ese.16.14.19833-en"},{"issue":"7","key":"1683_CR9","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1128\/AAC.00325-11","volume":"55","author":"M Ohnishi","year":"2011","unstructured":"Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011;55(7):3538\u201345.","journal-title":"Antimicrob Agents Chemother"},{"key":"1683_CR10","doi-asserted-by":"crossref","unstructured":"Forsyth S, Penney P, Rooney G. Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations. Int J STD AIDS. 2011;22(5):296\u20137.","DOI":"10.1258\/ijsa.2009.009191"},{"key":"1683_CR11","unstructured":"Public Health England. Health Protection Report. 2016;10(15). https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/517644\/hpr1516.pdf ."},{"issue":"1","key":"1683_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/jac\/dkh272","volume":"54","author":"DM Livermore","year":"2004","unstructured":"Livermore DM, Alexander S, Marsden B, et al. Activity of ertapenem against Neisseria gonorrhoeae. J Antimicrob Chemother. 2004;54(1):280\u20131.","journal-title":"J Antimicrob Chemother"},{"key":"1683_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2334-13-40","volume":"13","author":"B Olsen","year":"2013","unstructured":"Olsen B, Pham TL, Golparian D, Johansson E, Tran HK, Unemo M. Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011. BMC Infect Dis. 2013;13:40.","journal-title":"BMC Infect Dis."},{"key":"1683_CR14","unstructured":"Golparian D FP, Ohnishi M, Jensen JS, Unemo M. In vitro activity of solithromycin (CEM-101) against clinical Neisseria gonorrhoeae isolates displaying various types of antimicrobial resistance profiles. Clinical Microbiology and Infection Conference: 22nd European Congress of Clinical Microbiology and Infectious Diseases London United Kingdom Conference Start: 20120331 Conference End: 20120403. Conference Publication: (var pagings). 2012;18:391."},{"issue":"7","key":"1683_CR15","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1128\/AAC.00326-12","volume":"56","author":"M Unemo","year":"2012","unstructured":"Unemo M, Golparian D, Limnios A, et al. In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea? Antimicrob Agents Chemother. 2012;56(7):3603\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1683_CR16","first-page":"440","volume":"47","author":"J Panduro","year":"1971","unstructured":"Panduro J. Treatment of acute gonorrhoea with a single oral dose of rifampicin. Br J Vener Dis. 1971;47(6):440\u20132.","journal-title":"Br J Vener Dis"},{"issue":"5","key":"1683_CR17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1056\/NEJM198707303170504","volume":"317","author":"JW Boslego","year":"1987","unstructured":"Boslego JW, Tramont EC, Takafuji ET, et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med. 1987;317(5):272\u20138.","journal-title":"N Engl J Med"},{"issue":"8","key":"1683_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/sextrans-2012-050604","volume":"88","author":"D Dowell","year":"2012","unstructured":"Dowell D, Kirkcaldy RD. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Sex Transm Infect. 2012;88(8):589\u201394.","journal-title":"Sex Transm Infect"},{"key":"1683_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/2046-4053-3-104","volume":"3","author":"E Hathorn","year":"2014","unstructured":"Hathorn E, Dhasmana D, Duley L, Ross JD. The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review. Syst Rev. 2014;3:104.","journal-title":"Syst Rev."},{"issue":"8","key":"1683_CR20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/cid\/ciu521","volume":"59","author":"RD Kirkcaldy","year":"2014","unstructured":"Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis. 2014;59(8):1083\u201391.","journal-title":"Clin Infect Dis"},{"key":"1683_CR21","unstructured":"British National Formulary. https:\/\/www.bnf.org\/ ."},{"key":"1683_CR22","unstructured":"Hayward SR, Harding J, Molloy R, Land L, Longcroft-Neal K, Moore D, Ross JDC. Adverse effects of single dose gentamicin in adults: a systematic review. Oral Presentation IUSTI World Confree 2016, Marrakesh, Morocco. 2016."},{"issue":"3","key":"1683_CR23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/jac\/dkq476","volume":"66","author":"SA Chisholm","year":"2011","unstructured":"Chisholm SA, Quaye N, Cole MJ, et al. An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. J Antimicrob Chemother. 2011;66(3):592\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"1683_CR24","unstructured":"British Association for Sexual Health and HIV (BASHH) Clinical Effectiveness Group Guidelines. https:\/\/www.bashh.org\/guidelines ."},{"key":"1683_CR25","doi-asserted-by":"crossref","unstructured":"Brown LB, Krysiak R, Kamanga G, et al. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis. 2010;37(3):169\u201372.","DOI":"10.1097\/OLQ.0b013e3181bf575c"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-016-1683-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-016-1683-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-016-1683-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T18:23:56Z","timestamp":1657823036000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-016-1683-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,24]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1683"],"URL":"https:\/\/doi.org\/10.1186\/s13063-016-1683-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,24]]},"article-number":"558"}}